QSOA Stock Overview Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Surface Oncology, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Surface Oncology Historical stock prices Current Share Price US$0.99 52 Week High US$1.41 52 Week Low US$0.52 Beta 1.75 1 Month Change 16.19% 3 Month Change 36.16% 1 Year Change -27.10% 3 Year Change -82.41% 5 Year Change -88.77% Change since IPO -90.74%
Recent News & Updates
Surface Oncology, Inc. Files Form 15 Sep 19 Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.
Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market Jul 11
Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million. Jun 18
Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021) Mar 10
Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement Jan 13 See more updates
Surface Oncology, Inc. Files Form 15 Sep 19 Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.
Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market Jul 11
Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million. Jun 18
Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021) Mar 10
Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement Jan 13
Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology Jan 10
Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors Jan 06
Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.44 loss in 3Q 2021) Nov 03
Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting Sep 15
Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.43 loss in 2Q 2021) Aug 04
Surface Oncology Appoints Carsten Brunn to Board of Directors Jun 30 Surface Oncology, Inc. Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma Jun 21
Surface Oncology, Inc. Presents New SRF388 Clinical Data At 2022 American Society of Clinical Oncology Annual Meeting May 27
First quarter 2022 earnings released: EPS: US$0.13 (vs US$0.37 loss in 1Q 2021) May 10
Surface Oncology, Inc. to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting Apr 28 Surface Oncology, Inc. Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer Apr 16
Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study Apr 01
Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors Mar 04
Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors Mar 03
Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021 Dec 03
Surface Oncology Announces FDA Clearance of IND Application for GSK4381562 Dec 02
Investor sentiment deteriorated over the past week Nov 13
Investor sentiment improved over the past week Sep 21
Investor sentiment deteriorated over the past week Aug 05
Investor sentiment deteriorated over the past week Jun 10
Surface Oncology Announces the Presentation of New Data from the Ongoing Phase 1 Studies of SRF388 and SRF617 Jun 05
Investor sentiment improved over the past week May 20
First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.81 profit in 1Q 2020) May 07
Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX). May 04
Investor sentiment deteriorated over the past week Mar 30
Surface Oncology Collaborates with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors Mar 11
Revenue beats expectations Mar 11
Full year 2020 earnings released: EPS US$1.67 (vs US$1.97 loss in FY 2019) Mar 11
New 90-day low: €5.95 Mar 05 Surface Oncology, Inc. Announces Resignation of Daniel S. Lynch as Member and Chairman, Effective April 1, 2021
Surface Oncology, Inc. Announces Executive Changes, Effective April 1, 2021 Feb 12
New 90-day high: €9.20 Jan 13
Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program Dec 19
New 90-day high: €8.75 Dec 16
Surface Oncology, Inc. Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer Nov 12
Revenue in line with expectations Nov 11
Surface Oncology to Present Srf388 and Srf114 Preclinical Data At the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference Nov 10
Surface Oncology, Inc. Announces Preclinical Data on SRF388 Oct 27
New 90-day high: €6.05 Oct 06
New 90-day high - €5.95 Sep 03
Earnings released Aug 11
Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell Microcap Value Index Jul 02 Shareholder Returns QSOA DE Biotechs DE Market 7D -0.7% 6.0% 1.7% 1Y -27.1% -5.6% 9.4%
See full shareholder returns
Return vs Market: QSOA underperformed the German Market which returned 5.9% over the past year.
Price Volatility Is QSOA's price volatile compared to industry and market? QSOA volatility QSOA Average Weekly Movement 12.0% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: QSOA's share price has been volatile over the past 3 months.
Volatility Over Time: QSOA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No.
Show more Surface Oncology, Inc. Fundamentals Summary How do Surface Oncology's earnings and revenue compare to its market cap? QSOA fundamental statistics Market cap €60.83m Earnings (TTM ) -€86.46m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) QSOA income statement (TTM ) Revenue US$0 Cost of Revenue US$67.00m Gross Profit -US$67.00m Other Expenses US$25.50m Earnings -US$92.50m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/09/08 03:40 End of Day Share Price 2023/09/07 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Surface Oncology, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Michael Ulz Baird Justin Zelin BTIG Joshua Schimmer Evercore ISI
Show 3 more analysts 
